- Home
- LYFT vs APGE Comparison
LYFT vs APGE Comparison
Compare LYFT & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LYFT | APGE |
|---|---|---|
| Founded | 2007 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.7B |
| IPO Year | 2019 | 2023 |
Fundamental Metrics
Financial Performance| Metric | LYFT | APGE |
|---|---|---|
| Price | $13.73 | $82.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 29 | 13 |
| Target Price | $20.07 | ★ $109.67 |
| AVG Volume (30 Days) | ★ 13.1M | 517.2K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11250.00 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $6,316,261,000.00 | N/A |
| Revenue This Year | $17.33 | N/A |
| Revenue Next Year | $12.29 | N/A |
| P/E Ratio | $346.63 | ★ N/A |
| Revenue Growth | ★ 9.16 | N/A |
| 52 Week Low | $12.46 | $34.34 |
| 52 Week High | $25.54 | $95.32 |
Technical Indicators
Market Signals| Indicator | LYFT | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 43.32 | 46.96 |
| Support Level | $12.88 | $80.52 |
| Resistance Level | $14.24 | $84.56 |
| Average True Range (ATR) | 0.56 | 3.55 |
| MACD | -0.07 | -0.73 |
| Stochastic Oscillator | 22.01 | 15.72 |
Price Performance
Historical ComparisonAbout LYFT Lyft Inc.
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.